The global pharmaceuticals market is experiencing constant growth due to the worldwide increase in life expectancy, as well as the increasing incidence of chronic and infectious diseases. The steadily increasing demand for innovative drugs has thus t ....see more
The global CRO services market in terms of revenue was estimated to be worth $76.6 billion in 2023 and is poised to reach $127.3 billion by 2028, growing at a CAGR of 10.7% from 2023 to 2028. Key players in the CRO services market include IQVIA (US), Laboratory Corporation of America Holdings (US), PPD (US), ICON (US), WuXi AppTec (China), Syneos Health (US), Charles River Laboratories International (US), and Medpace Holdings (US).
The global inspection machines market in terms of revenue was estimated to be worth $721 million in 2022 and is poised to reach $905 million by 2027, growing at a CAGR of 4.7% from 2022 to 2027. The prominent players in this market are Robert Bosch GmbH (Germany), Körber AG (Germany), METTLER-TOLEDO International Inc. (US), Thermo Fisher Scientific (US), and Teledyne Technologies Incorporated (US).
The global Pharmaceutical Gelatin Market in terms of revenue was estimated to be worth $1.1 billion in 2022 and is poised to reach $1.5 billion by 2027, growing at a CAGR of 5.5% from 2022 to 2027. The leading players in this market are Darling Ingredients, Inc. (US), Gelita AG (Germany), Tessenderlo Group (Belgium), Nitta Gelatin Inc. (Japan), and others.
The global active pharmaceutical ingredient market in terms of revenue was estimated to be worth $145.9 billion in 2022 and is poised to reach $216.4 billion by 2027, growing at a CAGR of 8.2% from 2022 to 2027. The key players in this market are Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK).
The single use consumables market is projected to reach USD 4.7 billion by 2027, at a CAGR of 16.6% during the forecast period. The prominent players in the single-use consumables market are Thermo Fisher Scientific, Inc. (US), Sartorius Stedim Biotech (France), Danaher Corporation (US), Merck KGaA (Germany), and Avantor, Inc. (US). These companies have adopted organic and inorganic growth strategies, such as product launches and acquisitions, to maintain their leading positions in the single-use consumables market.
The global Clinical Trial Supplies Market boasts a total value of $3.6 billion in 2022 and is projected to register a growth rate of 9.7% to reach a value of $5.7 billion by 2027. Key players in the Clinical trial supplies market include Thermo Fisher Scientific (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US).
The global fill finish manufacturing market in terms of revenue was estimated to be worth $9.2 billion in 2022 and is poised to reach $15.2 billion by 2027, growing at a CAGR of 10.7% from 2022 to 2027. The major companies in this market are Becton, Dickson and Company (US), Syntegon Technology GmbH (Germany), I.M.A. (Industria Macchine Automatiche) S.p.A. (Italy), Stevanato Group (Italy), West Pharmaceutical Services, Inc. (US), OPTIMA Packaging Group GmbH (Germany), Bausch+Strobel (Germany), Groninger & Co. GmbH (Germany), and Gerresheimer AG (Germany).
The global Cardiac Safety Services Market in terms of revenue was estimated to be worth $0.6 billion in 2022 and is poised to reach $1.0 billion by 2027, growing at a CAGR of 11.2% from 2022 to 2027. Key players in the Market includes Laboratory Corporation of America Holdings (US), Koninklijke Philips N.V. (Netherlands), Clario (US), Banook Group (France), IQVIA (US), Biotrial (France), Certara (US), Celerion (US), Medpace (US), Ncardia (Netherlands), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon (China), Pharmaceutical Product Development (US), and SGS (Switzerland).
The global enteral feeding formulas market size is Projected to reach USD 8.2 billion by 2027, growing at a CAGR of 9.5%. Prominent players in this market are Abbott (US), Nestlé S.A. (Switzerland), Danone S.A. (France), Fresenius Kabi (Germany), B. Braun Melsungen AG (Germany), Otsuka Holding Co. Ltd. (Japan), Nutritional Medicinals, LLC (US), Kate Farms (US), Medtrition Inc. (US), Victus, Inc. (US), Global Health Products, Inc. (US), Meiji Holdings Co., Ltd. (Japan), Reckitt Benckiser Group PLC. (UK), Hormel Foods Corporation (US), DermaRite Industries, LLC. (US), Medline Industries, LP. (US), Real Food Blends (US), and Ajinomoto Cambrooke, Inc. (US).
The global overactive bladder treatment market size is projected to reach USD 4.2 Billion by 2027, at a CAGR of 3.6%. The prominent players Astellas Pharma (Japan), Teva Pharmaceutical Industries (Israel), Pfizer (US), Medtronic (Ireland), AbbVie (US), Viatris (US), Hisamitsu Pharmaceutical (Japan), Johnson & Johnson Services (US), Endo Pharmaceuticals Lupin (India) , Amneal Pharmaceuticals (US), Sun Pharmaceutical Industries (India) and among others.
The global pharmaceutical excipients market boasts a total value of $8.6 billion in 2022 and is projected to register a growth rate of 5.9% to reach a value of $11.5 billion by 2027. Some of the key players in the Market are Ashland Global Holdings, Inc (US), International Flavors & Fragrances, Inc. (US), BASF SE (Germany), Evonik Industries AG (Germany), Roquette Frčres (France), Associated British Foods plc (UK), Archer Daniels Midland Company (US), Lubrizol Corporation (US), Innophos Holdings (US), Kerry Group plc (Ireland), Wacker Chemie AG (Germany), Air Liquide (France), Dow Chemicals (US), Colorcon (US), DMV-Fonterra Excipients (Germany), JRS Pharma GmbH (Germany), Meggle GmbH & Co Kg (Germany), Finar Limited (India), Fuji Chemical Industries Co., Ltd (Japan), Merck KGaA (Germany), Captisol (US), Ideal Cures Pvt. Ltd (India), Corel Pharma Chem (India), Biogrund GmbH (Germany), Nitika Pharmaceutical Specialties Pvt. Ltd (India).
The global Topical Drug Delivery Market in terms of revenue was estimated to be worth $207.4 billion in 2022 and is poised to reach $317.8 billion by 2027, growing at a CAGR of 8.9% from 2022 to 2027. The prominent players Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Boehringer Ingelheim International GmBH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol Myers Squibb (US), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India).
The global High Potency APIs Market is projected to reach USD 39.6 billion by 2027, at a CAGR of 10.1% during the forecast period. The major players in the HPAPI market include Pfizer, Inc. (US), F. Hoffmann-La Roche (Switzerland), Sanofi (France), Bristol-Myers Squibb Company (US), Bayer AG (Germany), Novartis International AG (Switzerland), Boehringer Ingelheim International GmbH. (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), Merck & Co., Inc. (US), AbbVie (US), and Viatris Inc. (US).
The global Pharmaceutical Packaging Equipment Market in terms of revenue was estimated to be worth $8.4 billion in 2022 and is poised to reach $11.9 billion by 2027, growing at a CAGR of 7.2% from 2022 to 2027. Prominent players in the pharmaceutical packaging equipment market include Robert Bosch GmbH (Syntegon Technology GmbH) (Germany), IMA S.p.A. (Italy), Körber AG (Germany), Coesia S.p.A (Italy), Marchesini Group S.p.A (Italy), Bausch+Ströbel Maschinefabrik Ilshofen GmbH+Co. KG (Germany), Romaco Group (Germany), Uhlmann Group (Germany), Maquinaria Industries Dara, SL (US) and MULTIVAC Group (Germany).
The global clinical trials market in terms of revenue was estimated to be worth $38.7 billion in 2021 and is poised to reach $52.0 billion by 2026, growing at a CAGR of 6.1% from 2021 to 2026. Expanding number of clinical trials along with robust investment in pharmaceutical R&D are some of the key driving factors of the clinical trials market.
The global Drug Discovery Services Market in terms of revenue was estimated to be worth $16.1 billion in 2021 and is poised to reach $31.4 billion by 2026, growing at a CAGR of 14.3% from 2021 to 2026. The key players operating in this market are Laboratory Corporation of America Holdings (US), Charles River Laboratories International Inc. (US), WuXi AppTec (China), and Thermo Fisher Scientific Inc (US).
The vaccines market size is projected to reach USD 67.2 billion by 2026, at a CAGR of 10.2%. Key players operating in the global vaccines market include GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Sanofi SA (France), and Pfizer, Inc. (US).
The Cleanroom Technologies Market is expected to grow from USD 7.1 billion in 2021 to USD 9.6 billion by 2026, at a compound annual growth rate (CAGR) of 6.2% during the forecast period.The prominent players Azbil Corporation (Japan), Kimberly-Clark Corporation (US), Ardmac (Ireland), Clean Air Products (US), Labconco Corporation (US), Dynarex Corporation (US), DuPont de Nemours, Inc. (US), Illinois Tool Works, Inc. (US), Taikisha Ltd. (Japan), Exyte AG (Germany), COLANDIS GmbH (Germany), ABN Cleanroom Technology (Belgium), Clean Rooms International, Inc. (US), and, Bouygues Group (France).
The global prostate health market is projected to reach USD 48.9 billion by 2026, at a CAGR of 9.0% during the forecast period. Some of the prominent players operating in the prostate health market are Eli Lilly and Company (US), Pfizer Inc. (US), Merck & Co., Inc. (US), GlaxoSmithKline plc. (UK), Abbott (US), and Astellas Pharma Inc. (Japan) and other players.
The ear health market is expected to grow from USD 1.4 billion in 2021 to USD 1.9 billion by 2026, at a compound annual growth rate (CAGR) of 6.3% during the forecast period. The prominent players Sonova Holdings AG (Switzerland), Olympus Corp. (Japan), William Demant Holdings A/S (Denmark), Cochlear Limited (Australia), Stryker Corporation (US), Johnson & Johnson (US), Novartis (Switzerland), Karl Storz GMBH & Co. KG (Germany), Medtronic Plc (Ireland), Oscar Remedies Pvt Ltd. (India), and InnerScope Hearing Technologies (US).
The animal parasiticides market is expected to grow from USD 9.7 billion in 2021 to USD 13.7 billion by 2026, at a compound annual growth rate (CAGR) of 7.2% during the forecast period.Zoetis Inc. (US), Elanco Animal Health Incorporated (US), Virbac (France), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Ceva Santé Animale (France), Vetoquinol S.A. (France), PetIQ, Inc. (US), Norbrook (Ireland), and Bimeda Animal Health (US).
The global pharmaceutical contract manufacturing market in terms of revenue was estimated to be worth $120.6 billion in 2021 and is poised to reach $171.3 billion by 2026, growing at a CAGR of 7.3% from 2021 to 2026. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, the growing focus on specialty medicines, growth in the nuclear medicine sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.
The global biosimilars market in terms of revenue was estimated to be worth $15.6 billion in 2021 and is poised to reach $44.7 billion by 2026, growing at a CAGR of 23.5% from 2021 to 2026. Prominent players in this market are Novartis AG (Switzerland), Pfizer, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), Amgen, Inc. (US) and Eli Lilly and Company (US).
The global nuclear medicine market in terms of revenue was estimated to be worth $4.8 billion in 2021 and is poised to reach $7.5 billion by 2026, growing at a CAGR of 9.0% from 2021 to 2026. Some of the prominent players operating in this market includes Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaţý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa)
The empty capsules market size is projected to reach USD 3.7 billion by 2026, at a CAGR of 7.2% during the forecast period. The prominent players operating in this market are Capsugel (US), ACG Worldwide (India), Qualicaps (US), Suheung Co. Ltd. (Korea), CapsCanada Corporation (Canada) and others
The animal antimicrobials and antibiotics market is expected to grow from USD 3.6% between 2021 to USD 5.6 billion by 2026, at a compound annual growth rate (CAGR) of 3.6% during the forecast period.Boehringer Ingelheim (Germany), Zoetis Inc. (US), Elanco Animal Health (US), Merck & Co. Inc (US), Phibro Animal Health (US), Virbac (France), Vetoquinol S.A. (France), Ceva Santé Animale (France), Dechra Pharmaceuticals Plc (UK), Kyoritsu Seiyaku (Japan), Tianjin Ringpu (China), HIPRA (Spain), Zydus Animal Health (US), China Animal Husbandry (China), and Inovet (Belgium).
The Tablet Coatings Market is expected to grow from USD “Old” to USD 969 million by 2025, at a CAGR of 5.6% during the forecast period. The prominent players in this market are Colorcon Inc. (US), Sensient Technologies Corporation (US), BASF SE (Germany), Evonik Industries AG (Germany), Ashland Global Holdings Inc. (US), DuPont De Numeours Inc. (US), Kerry Group plc (Ireland), Roquette Freres (France), Eastman Chemical Company (US), Air Liquide S.A. (France), and Merck KGaA (Germany).
The US general anesthesia drugs market size is projected to reach USD 2.4 billion by 2025, at a CAGR of 3.4% during the forecast period. Some of the key players include Baxter International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US), Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA (Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex (Canada).
The global osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025, at a CAGR of 8.7%. The major players operating in this market are Sanofi (France), Horizon Therapeutics PLC (Ireland), Johnson & Johnson (US), GlaxoSmithKline PLC (UK), Bayer AG (Germany), Abbott (US), Pfizer, Inc. (US), Eli Lilly (US), Anika Therapeutics, Inc. (US), Novartis AG (Switzerland), Ferring Pharmaceuticals (Switzerland), Bioventus (US), Zimmer Biomet Holdings, Inc. (US), Fidia Farmaceutici s.p.a. (Italy), Flexion Therapeutics, Inc. (US), Pharmed Limited (India), Virchow Biotech (India), Kitov Pharmaceuticals Ltd. (Israel), Assertio Therapeutics, Inc. (US), Atnahs (UK), Almatica Pharma LLC (US), OrthogenRx (US), LABRHA (France), Hanmi Pharm. Co., Ltd. (Korea), and Laboratorio Reig Jofre (Spain).
The Asia-Pacific Animal Health Market is expected to grow from USD 15.6 billion in 2020 to USD 22.1 billion by 2025, at a CAGR of 7.2% during the forecast period. Some of the prominent players in this market are Boehringer Ingelheim (Germany), Zoetis Inc. (US), Elanco Animal Health (US), Merck & Co. Inc (US), Phibro Animal Health (US), Virbac (France), Vetoquinol S.A (France), Ceva Sante Animale (France), Dechra Pharmaceuticals Plc. (UK), Kyoritsu Seiyako (Japan), Tianjin Ringpu (China), China Animal Husbandry (China), and Jinyu Bio-Technology (China).
The global freeze-drying/lyophilization equipment market is expected to grow USD 7.3 billion by 2025, at a CAGR of 8.2% during the forecasting period. Some of the prominent players in this market are GEA Group (Germany), Azbil Corporation (Japan), Shanghai Tofflon Science Technology Co., Ltd. (China), IMA S.p.A. (Italy), SP Industries, Inc. (US), HOF Enterprise Group (Germany), Labconco Corporation (US), Martin Christ Gefriertrocknungsanlagen GmbH (Germany), Millrock Technology, Inc. (US), and OPTIMA Packaging Group GmbH (Germany).
The immunotherapy drugs market size is projected to reach USD 274.6 billion by 2025, at a CAGR of 11.0% during the forecast period. Some of the prominent players in the market are F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), and Merck & Co (US) are the key players operating in the immunotherapy drugs market. Others are Novartis International AG (UK), Johnson & Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany).
The veterinary vaccines market is projected to reach USD 11.3 billion by 2025 at a CAGR of 7.2% during the forecast period. The prominent players in the veterinary vaccines market include Zoetis (US), Merck (US), Boehringer Ingelheim (Germany), Elanco (US), Ceva (France), Phibro Animal Health Corporation (US), and Virbac SA (France). Major players have focused on product launches, agreements, and partnerships to increase their shares in the global veterinary vaccines market.
The COVID-19 vaccines & drugs market is expected to grow from USD 2,273 million in 2022 to USD 1,401 million by 2025 at a compound annual growth rate (CAGR) of 14.9% during the forecast period.Key players in the COVID-19 vaccines market include Pfizer Inc. (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc. (UK), Sanofi (France) Serum Institute of India (India), among others. Major players in the COVID-19 drugs market include Gilead Sciences, Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Janssen Pharmaceuticals, Inc. (Belgium) among others.
The North American Nuclear Medicine/Radiopharmaceuticals Market is expected to grow from USD 2.2 billion in 2019 to USD 2.7 billion by 2024, at a CAGR of 4.1% during the forecast period. The prominent players in the global North American nuclear medicine market include Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaţý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), and NTP Radioisotopes (South Africa).
The global womens healthcare market size is projected to reach USD 17.8 billion by 2024, at a CAGR of 13.2%. The prominent players in this market includes Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), Apothecus Pharmaceutical (US), Eli Lilly And Company (US), Novartis AG (Switzerland), and Johnson & Johnson (US).
The Stable Isotope Labeled Compounds Market is projected to reach USD 312 million by 2024, at a CAGR of 3.0% during the forecast period. The prominent players in this market include PerkinElmer Inc. (US), Merck KGaA (Germany), Cambridge Isotope Laboratories, Inc. (US), URENCO Limited (UK), IsoSciences, LLC (US), Medical Isotopes, Inc. (US), Omicron Biochemicals, Inc. (US), Trace Sciences International (US), Alsachim (France), Taiyo Nippon Sanso Corporation (Japan), and Rotem Industries Israel Ltd. (Israel).
The global bioprocess validation market size is projected to reach USD 360 million by 2024, at a CAGR of 14.6%. The prominent players operating in this market are Merck KGaA (Germany), Sartorius Stedim Biotech (Sartorius AG) (France), Pall Corporation (US), SGS S.A. (Switzerland), Eurofins Scientific (Luxembourg), Cobetter Filtration Equipment Co., Ltd. (China), Toxikon Corporation (US), DOC S.r.l. (Italy), MEISSNER FILTRATION PRODUCTS, INC. (US), and Thermo Fisher Scientific (US).
The healthcare distribution market is projected to reach USD 1,048.4 billion by 2024, at a CAGR of 6.5%. The prominent players operating in the healthcare distribution market are McKesson Corporation (US), AmerisourceBergen Corporation (US), Cardinal Health, Inc. (US), Owens & Minor, Inc. (US), Morris and Dickson Co., LLC (US), KeySource Medical, Inc. (US), Rochester Drug Cooperative, Inc. (US), Henry Schein Inc. (US), Smith Drug Company (US), FFF Enterprises (US), Patterson Companies Inc. (US), Mutual Drug (US), Shanghai Pharmaceutical Group Co., Ltd. (China), Medline Industries (US), PHOENIX Group (Germany), and CuraScript SD (US).
The leukemia therapeutics market is projected to reach USD 17.1 billion by 2024, at a CAGR of 6.8%. Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies. The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
The vitamin D therapy market is projected to reach USD 3.3 billion by 2024 from USD 1.9 billion in 2019, at a CAGR of 11.6% during the forecast period. Growth in this market is largely driven by the growing awareness about vitamin D deficiency and the presence of a large target patient population. On the other hand, the fortification of foods is likely to challenge the growth of this market. Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).
The European hemostats and sealants market is projected to reach USD 89 million by 2024 from USD 63 million in 2019, at a CAGR of 7.0%. The growth of this market is majorly driven by the launch of new products and favorable reimbursement scenario. However, the shift toward minimally invasive surgeries and adverse effect of hemostats are the major factors restraining the growth of this market. B. Braun (Germany), Medtronic (Ireland), C. R. Bard (US), Takeda (Japan), and Baxter (US).
The Latin America pharmaceutical excipients market is projected to reach USD 579 million by 2024 from USD 403 million in 2019, at a CAGR of 7.5%. Growth in this region is driven by the growing pharmaceutical industry in Latin American countries such as Brazil, Mexico, and Argentina; increasing focus of MNCs on investing in the pharmaceutical and healthcare sectors in Latin America; rapid growth in aging population & the subsequent increase in the prevalence of related diseases; and the availability of local and government funding for R&D activities. Prominent players in the Latin America pharmaceutical excipients market are DowDuPont (US), Roquette (France), Ashland (US), BASF (Germany), and Kerry Group (Ireland).
The transdermal drug delivery system market is projected to reach USD 7.1 billion by 2023, growing at a CAGR of 4.5%. The growth of this market is primarily driven by factors such as the increase in the prevalence of chronic diseases and technological advancements in transdermal drug delivery systems. The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).
The global superdisintegrants market is projected to reach USD 536.5 million by 2023, growing at a CAGR of 7.9%. The prominent players in the global superdisintegrants market are Ashland Inc. (US), BASF SE (Germany), DowDuPont (US), JRS Pharma (Germany), DFE Pharma (Germany), Roquette Freres (France), Asahi Kasei Corporation (Japan), Merck KGaA (Germany), Corel Pharma Chem (India), and Avantor Performance Materials, LLC (US).
The global oncology nutrition market is expected to reach USD 2.21 Billion by 2023 from USD 1.46 Billion in 2018, at a CAGR of 8.7%. Factors such as shifting focus from parenteral to enteral nutrition, increasing incidence of cancer, growing demand for nutritional feeding in the homecare sector, rising number of patients being treated for malnutrition, and increasing quality of clinical research on nutritional interventions are driving the market growth. The prominent players in the oncology nutrition market are Abbott Laboratories (US), Nestle S.A. (Switzerland), Danone (France), Fresenius Kabi AG (Germany), and B. Braun Melsungen AG (Germany).
The Parkinson's disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%. The market is being driven by the growth in aging population and the associated increase in the prevalence of Parkinson’s disease and government funding for research. Some of the major players operating in the Parkinson’s disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
The Indian peptide drugs market is expected to reach USD 883.0 Million in 2022 from USD 381.8 Million in 2016 and is expected to register a CAGR of 15.0%. Factors such as increasing prevalence of chronic diseases, rising aging population, and increasing healthcare expenditure are contributing to the growth of this market. The Indian anticoagulant drugs market is expected to reach USD 170.2 Million in 2022 from USD 127.8 Million in 2016 and is expected to register a CAGR of 4.9%. Factors such as incidence of coagulation disorders and government support for pharmaceutical companies are contributing to the growth of this market. Some of the major players operating in the Indian anticoagulant drugs market are Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (US), Abbott Laboratories (U.S.), Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), Micro Labs Ltd. (India), and VHB Lifesciences (India).
The global continuous manufacturing market is projected to grow at a CAGR of 13.3%. Major players in this market include GEA Group AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bosch Packaging Technology (Germany), Coperion GmbH (Germany), and Glatt GmbH (Germany). Other players include KORSCH AG (Germany), Munson Machinery Company, Inc. (U.S.), L.B. Bohle Maschinen + Verfahren Gmbh (Germany), Gebrüder Lödige Maschinenbau GmbH (Germany), Baker Perkins Ltd. (U.K.), Scott Equipment Company (U.S.), and Sturtevant, Inc. (U.S.).
The global nasal drug delivery technology market is projected to grow at a CAGR of 6.5%. Key players in the nasal drug delivery technology market include Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Johnson& Johnson Services, Inc. (U.S.), Pfizer, Inc. (U.S.), AstraZeneca Plc.(U.S.), Aptar Group (U.S.), and GlaxoSmithKline plc (U.K.).